Ocular Therapeutix, Inc.
OCUL
$10.04
-$0.06-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.12% | 0.81% | -22.43% | -5.71% | -18.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.12% | 0.81% | -22.43% | -5.71% | -18.14% |
| Cost of Revenue | 5.89% | 53.09% | 24.10% | 40.18% | 74.62% |
| Gross Profit | -7.86% | -69.82% | -55.72% | -70.71% | -184.14% |
| SG&A Expenses | 40.46% | 19.96% | 17.58% | 27.63% | 33.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.86% | 39.55% | 21.61% | 35.52% | 57.99% |
| Operating Income | -21.39% | -46.03% | -36.31% | -49.35% | -93.87% |
| Income Before Tax | -16.15% | -38.34% | -33.62% | -90.22% | -54.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.15% | -38.34% | -33.62% | -90.22% | -54.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.15% | -38.34% | -33.62% | -90.22% | -54.91% |
| EBIT | -21.39% | -46.03% | -36.31% | -49.35% | -93.87% |
| EBITDA | -20.48% | -46.27% | -36.41% | -50.16% | -96.31% |
| EPS Basic | 10.89% | -4.58% | -0.69% | -72.72% | -48.83% |
| Normalized Basic EPS | 10.95% | -4.57% | 0.55% | -72.69% | -85.85% |
| EPS Diluted | 10.89% | -5.26% | -0.69% | -72.73% | -48.83% |
| Normalized Diluted EPS | 10.95% | -4.57% | 0.55% | -72.69% | -85.85% |
| Average Basic Shares Outstanding | 30.34% | 32.29% | 32.68% | 10.14% | 4.08% |
| Average Diluted Shares Outstanding | 30.34% | 32.29% | 32.68% | 10.14% | 4.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |